PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
738.04%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
40.95%
G&A growth 1.1-1.25x CRVO's 37.03%. Bill Ackman would demand evidence of necessary spending.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
178.81%
Operating expenses growth 50-75% of CRVO's 251.41%. Bruce Berkowitz would examine efficiency.
178.81%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-184.06%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-178.81%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-185.77%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-184.01%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-184.01%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-184.12%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-184.12%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.